The test is based upon Zeus’s own proprietary technology utilizing the enrichment and nucleic acid amplification of a target pathogen.
In addition to significantly improving assay performance over other technologies in this product space, the nasal methicillin-resistant Staphylococcus aureus (MRSA) test will be offered as a low cost alternative to the two currently FDA approved MRSA PCR products without sacrificing time to results or performance.
Available through the Zeus worldwide distribution network, the new MRSA test will enable healthcare professionals to identify carriers of this pathogen within two hours.